PMID- 35472755 OWN - NLM STAT- MEDLINE DCOM- 20220511 LR - 20231107 IS - 1876-035X (Electronic) IS - 1876-0341 (Print) IS - 1876-0341 (Linking) VI - 15 IP - 5 DP - 2022 May TI - Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. PG - 573-577 LID - S1876-0341(22)00084-3 [pii] LID - 10.1016/j.jiph.2022.04.001 [doi] AB - BACKGROUND: Two vaccines for COVID-19 have been approved and administered in the Kingdom of Saudi Arabia (KSA); Pfizer-BioNtech BNT162b2 and AstraZeneca-Oxford AZD1222 vaccines. The purpose of this study was to describe the real-world data on the outcome of single dose of these COVID-19 vaccines in a large cohort in KSA and to analyse demographics and co-morbidities as risk factors for infection post one-dose vaccination. METHODS: In this prospective cohort study, a total of 18,543 subjects received one dose of either of the vaccines at a vaccination centre in KSA, and were followed up for three to eight months. Data were collected from three sources; clinical data from medical records, adverse events (AEs) from a self-reporting system, and COVID-19 infection data from the national databases. The study was conducted during the pandemic restrictions on travel, mobility, and social interactions. RESULTS: The median age of participants was 33 years with an average body mass index of 27.3. The majority were males (60.1%). Results showed that 92.17% of the subjects had no COVID-19 infection post-vaccination as infection post-vaccination was documented for 1452 (7.83%). Diabetes mellitus 03), organ transplantation (p = 0.02), and obesity (p < 0.01) were associated with infection post-vaccination. Unlike vaccine type, being Saudi, male, or obese was associated with the occurrence breakthrough infections more than other parameters. AEs included injection site pain, fatigue, fever, myalgia, headache and was reported by 5.8% of the subjects. CONCLUSION: Single dose COVID-19 vaccines showed a protection rate of 92.17% up to eight months follow-up in this cohort. This rate in AZD1222 was higher than what have been previously reported in effectiveness studies and clinical trials. Obese, male, and Saudi were at higher risk of contracting the infection post-vaccination, Saudi and male might have more social interaction with the public when mobility and social interactions were limited during the pandemic. Side effects and AEs were within what has been reported in clinical trials. CI - Copyright (c) 2022. Published by Elsevier Ltd. FAU - Alharbi, Naif Khalaf AU - Alharbi NK AD - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Science (KSAU-HS), Riyadh, Saudi Arabia. Electronic address: harbina2@ngha.med.sa. FAU - Al-Tawfiq, Jaffar A AU - Al-Tawfiq JA AD - Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Infectious Disease Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Infectious Disease Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Alghnam, Suliman AU - Alghnam S AD - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Science (KSAU-HS), Riyadh, Saudi Arabia. FAU - Alwehaibe, Amal AU - Alwehaibe A AD - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia. FAU - Alasmari, Abrar AU - Alasmari A AD - Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. FAU - Alsagaby, Suliman A AU - Alsagaby SA AD - Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia. FAU - Alsubaie, Faisal AU - Alsubaie F AD - Assistant Agency for Preventive Health, Ministry of Health, Riyadh, Saudi Arabia. FAU - Alshomrani, Majid AU - Alshomrani M AD - King Saud bin Abdulaziz University for Health Science (KSAU-HS), Riyadh, Saudi Arabia; King Abdulaziz Medical City (KAMC), Ministry of National Guard - Health Affairs (MNG-HA), Riyadh, Saudi Arabia. FAU - Farahat, Fayssal M AU - Farahat FM AD - King Saud bin Abdulaziz University for Health Science (KSAU-HS), Riyadh, Saudi Arabia; King Abdulaziz Medical City (KAMC), Ministry of National Guard - Health Affairs (MNG-HA), Riyadh, Saudi Arabia. FAU - Bosaeed, Mohammad AU - Bosaeed M AD - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Science (KSAU-HS), Riyadh, Saudi Arabia; King Abdulaziz Medical City (KAMC), Ministry of National Guard - Health Affairs (MNG-HA), Riyadh, Saudi Arabia. FAU - Alharbi, Ahmad AU - Alharbi A AD - King Abdulaziz Medical City (KAMC), Ministry of National Guard - Health Affairs (MNG-HA), Riyadh, Saudi Arabia. FAU - Aldibasi, Omar AU - Aldibasi O AD - King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Science (KSAU-HS), Riyadh, Saudi Arabia. FAU - Assiri, Abdullah M AU - Assiri AM AD - Assistant Agency for Preventive Health, Ministry of Health, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20220406 PL - England TA - J Infect Public Health JT - Journal of infection and public health JID - 101487384 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - N38TVC63NU (BNT162 Vaccine) SB - IM CIN - J Infect Public Health. 2022 Nov;15(11):1167-1168. doi: 10.1016/j.jiph.2022.09.004. PMID: 36194995 MH - Adult MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - ChAdOx1 nCoV-19 MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Obesity/epidemiology MH - Prospective Studies MH - SARS-CoV-2 MH - Saudi Arabia/epidemiology MH - *Vaccines PMC - PMC8986276 OTO - NOTNLM OT - AZD1222 OT - BNT162b2 OT - COVID-19 OT - Single-dose OT - Vaccines COIS- Competing interests The authors declare no conflict of interest or competing interest. EDAT- 2022/04/27 06:00 MHDA- 2022/05/12 06:00 PMCR- 2022/04/06 CRDT- 2022/04/26 20:21 PHST- 2021/12/20 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/04/03 00:00 [accepted] PHST- 2022/04/27 06:00 [pubmed] PHST- 2022/05/12 06:00 [medline] PHST- 2022/04/26 20:21 [entrez] PHST- 2022/04/06 00:00 [pmc-release] AID - S1876-0341(22)00084-3 [pii] AID - 10.1016/j.jiph.2022.04.001 [doi] PST - ppublish SO - J Infect Public Health. 2022 May;15(5):573-577. doi: 10.1016/j.jiph.2022.04.001. Epub 2022 Apr 6.